-
Japan's cherry blossom season dazzles locals and tourists
-
EU ups mackerel quotas to match UK despite overfishing concerns
-
Crude rises, stocks drop as Houthi attacks escalate Iran war
-
Australian Rules player banned for wiping blood on face of opponent
-
Sheep culls put pressure on Greek feta cheese production
-
One man, his dog, and ChatGPT: Australia's AI vaccine saga
-
Israel PM restores access after Latin Patriarch blocked from Holy Sepulchre
-
Israel strikes Tehran as Trump says Iran deal may be reached 'soon'
-
Italy chase World Cup spot as Kosovo bid to make debut
-
Myanmar paves way for junta chief to become civilian president
-
'Long live the shah': Iranian diaspora back war at Washington rally
-
Taiwan opposition leader accepts Xi's invitation to visit China
-
French masonic lodge at heart of murky murder trial
-
US military building 'massive complex' beneath White House ballroom project: Trump
-
IPL captain takes pop at Cricket Australia over record-buy Green
-
G7 ministers set to tackle financial fallout of Mideast war
-
Premier League fans feel the pinch from ticket price hikes
-
Australia to halve fuel tax in response to Middle East war
-
Crude surges, stocks dive as Houthi attacks escalate Iran war
-
Air China resumes flights to North Korea after 6-year pause
-
NBA-best Thunder beat Knicks as Boston seal playoff spot
-
Australian fugitive shot dead by police after seven-month manhunt
-
King Kimi, Max misery, Bearman smash: Japan GP talking points
-
Philippines oil refinery secures 2.5 mn barrels of Russian crude
-
Trump says Russia can deliver oil to Cuba
-
All Blacks prop Williams out of Super Rugby season with back infection
-
Life with AI causing human brain 'fry'
-
Dubious AI detectors drive 'pay-to-humanize' scam
-
Test star Carey the hero as South Australia win Sheffield Shield final
-
Defending champ Kim Hyo-joo holds off Korda to win LPGA Ford Championship
-
Implacable Sinner overpowers Lehecka to win Miami Open
-
Australian police shoot dead fugitive wanted for killing officers
-
UK police question suspect after car hits pedestrians in English city
-
BioNxt Advances Semaglutide as First Application of Broad GLP-1 ODF Platform Strategy
-
World number two Sinner overpowers Lehecka to win Miami Open
-
Latin Patriarch to get immediate access to Holy Sepulchre: Netanyahu
-
Russian tanker heads to Cuba despite US oil blockade
-
Woodland takes Houston Open, first win since 2019 US Open
-
Italy's Bezzecchi wins fifth MotoGP in a row by taking US Grand Prix
-
Doue brace leads France past Colombia in friendly
-
Rheinmetall addresses row over CEO's Ukraine 'housewives' comment
-
Hungary's anxious rural voters will decide Orban's fate
-
Defiant Pochettino ready for 'even greater' Portugal test
-
Rohit and Rickelton power Mumbai to IPL win over Kolkata
-
Russian tanker nears Cuba, defying US oil blockade
-
'Project Hail Mary' tops N. America box office for second week
-
Forty new migratory species win international protection: UN body
-
Freed whale gets stranded again on German coast
-
Ter Stegen's World Cup chances 'very slim', says Nagelsmann
-
Pakistan hosts Saudi, Turkey, Egypt for talks on Mideast war
US authorizes first condom for use in anal sex
The US Food and Drug Administration (FDA) on Wednesday authorized the first condom for use during anal intercourse, in what was hailed as a victory for sexual health by experts.
Although people already use condoms for anal sex -- as is recommended by health agencies including the Centers for Disease Control and Prevention (CDC) -- regulators across the world had only previously allowed companies to officially market their products as "safe and effective" for vaginal use.
Sexual health advocates considered this an unmet public health need since unprotected anal intercourse carries the greatest risk of HIV transmission via sexual exposure, with one study finding that 69 percent of men who have sex with men would use condoms more frequently if they were FDA-indicated.
Wednesday's authorization of Global Protection Corp's One Male Condom follows a clinical trial involving more than 500 people, carried out by Emory University.
"The FDA's authorization of a condom that is specifically indicated, evaluated and labeled for anal intercourse may improve the likelihood of condom use during anal intercourse," said agency scientist Courtney Lias in a statement.
The condom is also indicated to prevent sexually transmitted infections -- and as a contraceptive -- during vaginal sex.
"We want people to have lots of sex -- but we also want them to be empowered and informed," said Davin Wedel, president of Global Protection Corp, which makes the condom brand that is available in 54 sizes, and incorporates a paper template to help each user find the right size.
The clinical trial involved 252 men who have sex with men and 252 men who have sex with women, aged between 18 and 54.
The FDA had said it would accept a five percent failure rate, which previous trials had failed to accomplish. The limit was easily surpassed in the new study, with the failure rate 0.68 percent for anal and 1.89 percent for vaginal intercourse.
The researchers behind the study, which was published in The Lancet's eClinicalMedicine, said one of the reasons the trial succeeded where others failed in the past was likely due to the provision of lubricant and inclusion of instructions on how to use the product.
Lubricant reduces friction, which in turn causes condom failure from slippage and breakage.
Another reason could be that participants were asked to keep mobile phone-based daily diaries, whereas past trials had asked volunteers to recall failure events up to several months later.
Monica Gandhi, an infectious disease doctor and medical director of an HIV clinic in San Francisco, welcomed the finding.
"The important thing about condoms is they don't just prevent HIV, but they prevent gonorrhea, chlamydia and syphilis," she told AFP, adding it was surprising that such an authorization had taken so long to achieve.
In its statement, the FDA said the green light could pave the way for more makers to apply for similar authorization if they show equivalent results.
K.Thomson--BTB